Evidence that C1s participates in the alternative complement pathway.
Purified C1s, subcomponent of C1, induced electrophoretic conversion of factor B and consumption of hemolytic C3 and C5 in sera genetically deficient in C2 or C4. Blocking of the hemolytic activity of C1s in C2-deficient serum by F(ab')2 anti-C1s resulted in inhibition of the alternative pathway, as indicated by the failure of zymosan or cobra venom factor to induce comsumption of C3 and C6. Zymosan also failed to activate the alternative pathway when C1s was absorbed from C1r-deficient serum using a solid immunoabsorbent. These data, showing that C1s participates in the alternative pathway under certain experimental conditions, suggest the interesing possibility that C1s is important in the activation sequence of both the classical and the alternative pathway more generally.
D000818:Animals; D000936:Antigen-Antibody Complex; D002021:Buffers; D003172:Complement C1 / Q000032:analysis / Q000302:isolation & purification / Q000378:metabolism*; D003175:Complement C2 / Q000032:analysis / Q000172:deficiency; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis / Q000172:deficiency; D003182:Complement C5 / Q000032:analysis; D003183:Complement C6 / Q000032:analysis; D003165:Complement System Proteins / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006801:Humans; D007106:Immune Sera / Q000302:isolation & purification; D011817:Rabbits; D012910:Snake Venoms / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
D000936:Antigen-Antibody Complex; D002021:Buffers; D003172:Complement C1; D003175:Complement C2; D003176:Complement C3; D003181:Complement C4; D003182:Complement C5; D003183:Complement C6; D007106:Immune Sera; D012910:Snake Venoms; D003165:Complement System Proteins; D015054:Zymosan